Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypertension and dementia.

A S Rigaud1, O Hanon, M L Seux

  • 1Department of Geriatrics, Hôpital Broca, CHU Cochin Port-Royal, Université René Descartes, Paris V 54/56 Rue Pascal, 75013 Paris, France. anne-sophie.rigaud@brc.ap-hop-paris.fr

Current Hypertension Reports
|December 6, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perspectives of French community-dwelling older adults on the use of digital services: a qualitative study based on interviews.

BMC geriatrics·2026
Same author

Primary Impact Trajectories of a Psychoeducational Program for Nursing Home Caregivers: Insights from Clinical Case Studies.

International medical case reports journal·2025
Same author

The pattern of cortical thickness associated with executive dysfunction in MCI and SCC: The MEMENTO cohort.

Revue neurologique·2024
Same author

[Translation into French and republication of: "Management of cancer-associated thromboembolism in vulnerable population"].

La Revue de medecine interne·2024
Same author

The free plasma amyloid Aβ<sub>1</sub><sub>-</sub><sub>42</sub>/Aβ<sub>1</sub><sub>-</sub><sub>40</sub> ratio predicts conversion to dementia for subjects with mild cognitive impairment with performance equivalent to that of the total plasma Aβ<sub>1</sub><sub>-</sub><sub>42</sub>/Aβ<sub>1</sub><sub>-</sub><sub>40</sub> ratio. The BALTAZAR study.

Neurobiology of disease·2024
Same author

Orthostatic hypotension: Review and expert position statement.

Revue neurologique·2023
Same journal

Neural Control of Tissue Perfusion: Emerging Evidence and Beyond.

Current hypertension reports·2026
Same journal

Correction to: Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?

Current hypertension reports·2026
Same journal

Intersection of Pediatric Hypertension and Cardiovascular-Kidney-Metabolic Disease.

Current hypertension reports·2026
Same journal

Combined Aldosterone Synthase and SGLT2 Inhibition: A Recipe for Success in CKD with Uncontrolled Blood Pressure?

Current hypertension reports·2026
Same journal

Leveraging the Electronic Health Record to Identify and Manage Resistant Hypertension.

Current hypertension reports·2026
Same journal

Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy?

Current hypertension reports·2026
See all related articles

As people live longer, cognitive disorders increase, especially after age 80. Antihypertensive treatment shows promise in reducing this risk, promoting healthier aging.

Area of Science:

  • Gerontology
  • Neurology
  • Public Health

Background:

  • Increased life expectancy correlates with a rise in cognitive disorders, particularly in individuals over 80.
  • Cognitive disorders present significant challenges, necessitating proactive identification and management of risk factors.
  • Identifying modifiable risk factors is crucial for mitigating the impact of cognitive decline.

Purpose of the Study:

  • To highlight the growing concern of cognitive disorders in an aging population.
  • To emphasize the importance of addressing risk factors for cognitive decline.
  • To explore the potential of antihypertensive treatment in reducing the risk of cognitive disorders.

Main Methods:

  • Review of existing literature on aging, cognitive disorders, and cardiovascular health.

Related Experiment Videos

  • Analysis of epidemiological data linking hypertension and cognitive decline.
  • Examination of clinical evidence supporting the efficacy of antihypertensive therapies.

    • Main Results:

    • Cognitive disorders significantly impact individuals over 80, posing a major health challenge.
    • Antihypertensive treatment has been shown to be associated with a reduced risk of cognitive disorders.
    • This suggests a potential pathway for intervention to promote cognitive health in aging populations.

    Conclusions:

    • Managing hypertension through antihypertensive treatment may be a key strategy in preventing cognitive disorders.
    • Early identification and management of risk factors, including hypertension, are vital for healthy aging.
    • Further research into the mechanisms and long-term effects of antihypertensive treatment on cognitive function is warranted.